ANI Pharmaceuticals is a leading pharmaceutical company that develops, manufactures, and markets both branded and generic prescription drugs. The company focuses on a variety of therapeutic areas and aims to provide treatments for patients with unmet medical needs. Its activities include research and development as well as commercializing its portfolio of products.
On July 13, 2026, an insider transaction occurred at ANI Pharmaceuticals. Cook Meredith, the Senior Vice President and General Counsel, sold 500 shares of common stock at a price of $81.84 per share. After this sale, Meredith's total holdings in the company amount to 77,390 shares.
This sale is part of a pattern of recent insider selling at the company. As highlighted by The Motley Fool, CFO Stephen P. Carey also sold shares. He sold 3,313 shares for about $285,000 on July 2 and 2,850 shares for around $240,000 on June 29. These sales followed a significant rise in the stock's price.
The company's recent stock performance follows positive company news. ANI Pharmaceuticals announced successful topline data from its Phase 4 SYNCHRONICITY clinical trial. The study, evaluating an implant for a chronic eye condition, met its main goals by showing improvements in vision. The company plans to present the full results at an upcoming medical meeting.
Currently, ANI Pharmaceuticals stock trades at $80.55 per share, with a market capitalization of approximately $1.83 billion. The stock's 52-week range is between $62.61 and $99.50. Market capitalization is the total value of a company's shares and is calculated by multiplying the share price by the number of outstanding shares, offering key investment insights.
